Company intelligence / Profile preview

Frontida Biosciences

Exton, Pennsylvania, United States

Ownership: Private
Employees: ~66
Development stage: Other

Overview

Frontida BioPharm was a CDMO specializing in oral solid dose formulations, including high-potency and controlled-release products, utilizing its patented Duragran granulation process. It served various therapeutic areas including oncology, cardiovascular, and musculoskeletal, operating manufacturing facilities in Pennsylvania and Illinois. The company was acquired by Adare Pharma Solutions on December 1, 2021.

Therapeutic areas: OncologyCardiovascularEndocrinology
Modalities: Small molecule (oral solid dose formulations)
Industry: Contract Manufacturing Organization

Partnerships

Affiliate of Frontage Laboratories

Beyond the preview

Go deeper on Frontida Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Frontida Biosciences.

Explore the full profile